Recent And Upcoming FDA Advisory Committee Meetings

Topic	Advisory Committee	Date
Novartis' Ilaris (canakinumab) for treatment of gouty arthritis attacks	Arthritis	June 21
Shire's Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema	Pulmonary and Allergy Drugs	June 23
Development issues for cellular and gene therapy products for retinal disorders, including efficacy endpoints in children and adults, potential safety issues related to repeat or second eye administration, and evaluation of product delivery into target site	Cellular, Tissue and Gene Therapies	June 29
Seattle Genetics' Adcetris (brentuximab vedotin) for relapsed or refractory Hodgkin's lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma	Oncologic Drugs	July 14
Bristol-Myers Squibb/AstraZeneca's dapagliflozin for glycemic control in adults with type 2 diabetes	Endocrinologic and Metabolic Drugs	July 19
Development program of an investigational gastroenterology drug; after a brief open period, the meeting will be closed to allow discussion including proprietary information	Gastrointestinal Drugs and Drug Safety and Risk Management	July 20 CLOSED
Centocor Ortho Biotech's Remicade (infliximab) for pediatric patients with moderately to severely active ulcerative colitis	Gastrointestinal Drugs	July 21
Topics including implementation of Quality by Design principles	Pharmaceutical Science and Clinical Pharmacology	July 27